Full Text Full Text (PDF) Correction (v165,p1495) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Sikich, L. Articles by Lieberman, J. A. Search for Related Content PubMed Citation Articles by Sikich, L. Articles by Lieberman, J. A. Child/Adolescent Psychiatry Atypical Neuroleptics Conventional Neuroleptics Schizophrenia Spectrum Disorders Related Articles

Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study

OBJECTIVE: Atypical (second-generation) antipsychotics are considered standard treatment for children and adolescents with early-onset schizophrenia and schizoaffective disorder. However, the superiority of second-generation antipsychotics over first-generation antipsychotics has not been demonstrated. This study compared the efficacy and safety of two second-generation antipsychotics (olanzapine and risperidone) with a first-generation antipsychotic (molindone) in the treatment of early-onset schizophrenia and schizoaffective disorder. METHOD: This double-blind multisite trial randomly assigned pediatric patients with early-onset schizophrenia and schizoaffective disorder to treatment with either olanzapine (2.5–20 mg/day), risperidone (0.5–6 mg/day), or molindone (10–140 mg/day, plus 1 mg/day of benztropine) for 8 weeks. The primary outcome was response to treatment, defined as a Clinical Global Impression (CGI) improvement score of 1 or 2 and 20% reduction in Positive and Negative Syndrome Scale (PANSS) total score after 8 weeks of treatment. RESULTS: In total, 119 youth were randomly assigned to treatment. Of these subjects, 116 received at least one dose of treatment and thus were available for analysis. No significant differences were found among treatment groups in response rates (molindone: 50%; olanzapine: 34%; risperidone: 46%) or magnitude of symptom reduction. Olanzapine and risperidone were associated with significantly greater weight gain. Olanzapine showed the greatest risk of weight gain and significant increases in fasting cholesterol, low density lipoprotein, insulin, and liver transaminase levels. Molindone led to more self-reports of akathisia. CONCLUSIONS: Risperidone and olanzapine did not demonstrate superior efficacy over molindone for treating early-onset schizophrenia and schizoaffective disorder. Adverse effects were frequent but differed among medications. The results question the nearly exclusive use of second-generation antipsychotics to treat early-onset schizophrenia and schizoaffective disorder. The safety findings related to weight gain and metabolic problems raise important public health concerns, given the widespread use of second-generation antipsychotics in youth for nonpsychotic disorders.

Related Articles:

New Findings on Antipsychotic Use in Children and Adolescents With Schizophrenia Spectrum Disorders

Randal G. Ross
Am J Psychiatry 2008 165: 1369-1372. [Full Text] [PDF]

This article has been cited by other articles:

				M. Alvarez-Jimenez, A. G. Parker, S. E. Hetrick, P. D. McGorry, and J. F. Gleeson Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis Schizophr Bull, November 9, 2009; (2009) sbp129v1. [Abstract] [Full Text] [PDF]

				C. U. Correll, P. Manu, V. Olshanskiy, B. Napolitano, J. M. Kane, and A. K. Malhotra Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents JAMA, October 28, 2009; 302(16): 1765 - 1773. [Abstract] [Full Text] [PDF]

				C. K. Varley and J. McClellan Implications of Marked Weight Gain Associated With Atypical Antipsychotic Medications in Children and Adolescents JAMA, October 28, 2009; 302(16): 1811 - 1812. [Full Text] [PDF]

				S. Crystal, M. Olfson, C. Huang, H. Pincus, and T. Gerhard Broadened Use Of Atypical Antipsychotics: Safety, Effectiveness, And Policy Challenges Health Aff., September 1, 2009; 28(5): w770 - w781. [Abstract] [Full Text] [PDF]

				R. M. WAUGAMAN Potential Lower Efficacy of Molindone Among First-Generation Antipsychotics Am J Psychiatry, April 1, 2009; 166(4): 491 - 491. [Full Text] [PDF]

				R. G. Ross New Findings on Antipsychotic Use in Children and Adolescents With Schizophrenia Spectrum Disorders Am J Psychiatry, November 1, 2008; 165(11): 1369 - 1372. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us